Beam Therapeutics (BEAM) News Today $24.49 -0.80 (-3.16%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Beam Therapeutics Inc. (NASDAQ:BEAM) Stake Boosted by Quest Partners LLCQuest Partners LLC grew its stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 410.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 36,193 shares of the company's stock after purchasing an additionaNovember 21 at 4:11 AM | marketbeat.comBeam Therapeutics Inc. (NASDAQ:BEAM) Sees Large Increase in Short InterestBeam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) saw a large increase in short interest during the month of October. As of October 31st, there was short interest totalling 12,310,000 shares, an increase of 10.3% from the October 15th total of 11,160,000 shares. Based on an average daily trading volume, of 890,600 shares, the short-interest ratio is currently 13.8 days.November 16, 2024 | marketbeat.comBeam TherapeuticsNovember 15, 2024 | forbes.comBeam Therapeutics management to meet virtually with Cantor FitzgeraldNovember 15, 2024 | markets.businessinsider.comBeam Therapeutics Inc. (NASDAQ:BEAM) Shares Acquired by Sumitomo Mitsui Trust Group Inc.Sumitomo Mitsui Trust Group Inc. lifted its holdings in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 59.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,552,829 shares of the company's stock after acquiNovember 15, 2024 | marketbeat.comBaillie Gifford & Co. Has $8.76 Million Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM)Baillie Gifford & Co. lowered its stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 42.6% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 357,698 shares of the company's stock after selling 265,942 shares during the period. Baillie GNovember 13, 2024 | marketbeat.comBeam Therapeutics participates in a conference call with JPMorganNovember 13, 2024 | markets.businessinsider.comBeam Therapeutics to Participate in 2024 Jefferies London Healthcare ConferenceNovember 12, 2024 | globenewswire.comHC Wainwright Brokers Decrease Earnings Estimates for BEAMNovember 12, 2024 | americanbankingnews.comFroedtert, Medical College on pace to be first to offer proton therapy in WisconsinNovember 11, 2024 | msn.comResearch Analysts Issue Forecasts for BEAM FY2024 EarningsBeam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Equities research analysts at HC Wainwright decreased their FY2024 EPS estimates for Beam Therapeutics in a research report issued on Wednesday, November 6th. HC Wainwright analyst P. Trucchio now expects that the company will earn ($4.43) perNovember 11, 2024 | marketbeat.comGiuseppe Ciaramella Sells 51,110 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) StockNovember 9, 2024 | insidertrades.comBeam Therapeutics Inc. (NASDAQ:BEAM) President Sells $1,347,259.60 in StockBeam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) President Giuseppe Ciaramella sold 51,110 shares of Beam Therapeutics stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $26.36, for a total transaction of $1,347,259.60. Following the completion of the transaction, the president now owns 109,150 shares in the company, valued at approximately $2,877,194. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.November 8, 2024 | marketbeat.comFY2024 EPS Estimate for Beam Therapeutics Lowered by AnalystBeam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Analysts at Leerink Partnrs lowered their FY2024 earnings per share estimates for shares of Beam Therapeutics in a research report issued to clients and investors on Wednesday, November 6th. Leerink Partnrs analyst M. Foroohar now forecasts thaNovember 8, 2024 | marketbeat.comARK Investment Management LLC Sells 1,095,040 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)ARK Investment Management LLC cut its holdings in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 14.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,531,099 shares of the company's stock after sellingNovember 8, 2024 | marketbeat.comBeam Therapeutics upgraded to Outperform from Market Perform at LeerinkNovember 7, 2024 | finance.yahoo.comBeam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A WatchNovember 7, 2024 | seekingalpha.comBeam Therapeutics' (BEAM) Buy Rating Reiterated at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $80.00 target price on shares of Beam Therapeutics in a research report on Thursday.November 7, 2024 | marketbeat.comWedbush Cuts Earnings Estimates for Beam TherapeuticsBeam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Equities research analysts at Wedbush dropped their FY2024 earnings per share (EPS) estimates for shares of Beam Therapeutics in a research report issued on Tuesday, November 5th. Wedbush analyst D. Nierengarten now forecasts that the company wNovember 7, 2024 | marketbeat.comWilliam Blair Has Negative Estimate for BEAM FY2024 EarningsBeam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - William Blair reduced their FY2024 earnings per share estimates for shares of Beam Therapeutics in a note issued to investors on Tuesday, November 5th. William Blair analyst S. Corwin now anticipates that the company will earn ($4.56) per shareNovember 7, 2024 | marketbeat.comBeam Therapeutics (NASDAQ:BEAM) Upgraded by Leerink Partnrs to Strong-Buy RatingLeerink Partnrs raised shares of Beam Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Wednesday.November 7, 2024 | marketbeat.comLeerink Partners Upgrades Beam Therapeutics (BEAM)November 7, 2024 | msn.comScotiabank Remains a Hold on Beam Therapeutics (BEAM)November 7, 2024 | markets.businessinsider.comBeam Therapeutics’ Promising Genetic Medicines and Strategic Advancements Justify Buy RatingNovember 7, 2024 | markets.businessinsider.comBeam stock rebounds as Leerink upgrades despite fatality in gene editing trialNovember 6, 2024 | msn.comBeam Therapeutics Third Quarter 2024 Earnings: EPS Misses ExpectationsNovember 6, 2024 | finance.yahoo.comBeam Therapeutics (NASDAQ:BEAM) Rating Increased to Outperform at Leerink PartnersLeerink Partners upgraded Beam Therapeutics from a "market perform" rating to an "outperform" rating and lifted their price target for the stock from $27.00 to $39.00 in a report on Wednesday.November 6, 2024 | marketbeat.comPatient death post BEAM-101 doesn’t seem related to Beam drug, says BMONovember 5, 2024 | markets.businessinsider.comBuy Rating Affirmed for Beam Therapeutics Due to Promising BEAM-101 Developments in Sickle Cell Disease TreatmentNovember 5, 2024 | markets.businessinsider.comGene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease TrialNovember 5, 2024 | finance.yahoo.comBeam stock falls after fatality in gene editing trialNovember 5, 2024 | seekingalpha.comBeam Therapeutics Inc. (BEAM) Q3 2024 Earnings Call TranscriptNovember 5, 2024 | seekingalpha.comBeam Therapeutics (NASDAQ:BEAM) Announces Quarterly Earnings Results, Misses Estimates By $0.04 EPSBeam Therapeutics (NASDAQ:BEAM - Get Free Report) posted its earnings results on Tuesday. The company reported ($1.17) EPS for the quarter, missing the consensus estimate of ($1.13) by ($0.04). The company had revenue of $14.30 million for the quarter, compared to the consensus estimate of $14.52 million. Beam Therapeutics had a negative net margin of 40.56% and a negative return on equity of 16.22%. The firm's revenue for the quarter was down 16.9% compared to the same quarter last year. During the same period last year, the company posted ($1.22) earnings per share.November 5, 2024 | marketbeat.comBeam Therapeutics (NASDAQ:BEAM) Shares Gap Down Following Weak EarningsBeam Therapeutics (NASDAQ:BEAM) Shares Gap Down After Earnings MissNovember 5, 2024 | marketbeat.comBeam Therapeutics Inc. Q3 Loss Misses EstimatesNovember 5, 2024 | markets.businessinsider.comBeam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority ProgramsNovember 5, 2024 | globenewswire.comBeam Therapeutics Inc. (NASDAQ:BEAM) Given Average Recommendation of "Moderate Buy" by BrokeragesBeam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) has been given an average rating of "Moderate Buy" by the ten research firms that are presently covering the firm, Marketbeat reports. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating on the coNovember 5, 2024 | marketbeat.comBeam Therapeutics's Earnings: A PreviewNovember 4, 2024 | benzinga.comBeam Therapeutics (NASDAQ:BEAM) Shares Up 6.5% - Still a Buy?Beam Therapeutics (NASDAQ:BEAM) Shares Up 6.5% - Time to Buy?November 4, 2024 | marketbeat.comBeam Therapeutics’ BEAM-101 Shows Promise in Sickle Cell Disease Treatment with Innovative Gene Editing ApproachOctober 31, 2024 | markets.businessinsider.comBeam Therapeutics (BEAM): Promising Gene Editing Stock with Base Editing TechnologyOctober 31, 2024 | msn.comBeam Therapeutics (BEAM) Scheduled to Post Quarterly Earnings on TuesdayBeam Therapeutics (NASDAQ:BEAM) will be releasing earnings before the market opens on Tuesday, November 5, Zacks reports.October 30, 2024 | marketbeat.comInternational Assets Investment Management LLC Makes New Investment in Beam Therapeutics Inc. (NASDAQ:BEAM)International Assets Investment Management LLC bought a new stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund bought 64,313 shares of the company's stock, valued at approximately $15,76October 30, 2024 | marketbeat.comBeam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual MeetingOctober 29, 2024 | globenewswire.comUsing proton beam therapy to treat heart rhythm disorderOctober 24, 2024 | msn.comBeam Therapeutics (BEAM): A Small-Cap Leader in Precision Genetic MedicineOctober 23, 2024 | msn.comScotiabank Initiates Coverage of Beam Therapeutics (BEAM) with Sector Perform RecommendationOctober 17, 2024 | msn.comBeam Therapeutics (NASDAQ:BEAM) Shares Down 6.6% on Insider SellingBeam Therapeutics (NASDAQ:BEAM) Shares Down 6.6% Following Insider SellingOctober 17, 2024 | marketbeat.comInsider Selling: Beam Therapeutics Inc. (NASDAQ:BEAM) President Sells 51,110 Shares of StockOctober 17, 2024 | insidertrades.comBeam Therapeutics (NASDAQ:BEAM) Earns Sector Outperform Rating from Analysts at ScotiabankScotiabank began coverage on shares of Beam Therapeutics in a report on Wednesday. They issued a "sector outperform" rating on the stock.October 16, 2024 | marketbeat.com Get Beam Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter. Email Address This Bull Market Indicator called NVDA at $116 (Ad)Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run… All you have to do is follow this link here BEAM Media Mentions By Week BEAM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BEAM News Sentiment▼0.580.45▲Average Medical News Sentiment BEAM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BEAM Articles This Week▼56▲BEAM Articles Average Week Get Beam Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NTLA News SGMO News EDIT News ALVR News DTIL News RGEN News HALO News KRYS News ADMA News ACLX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BEAM) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beam Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Beam Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BEAM Stock Alerts